33 related articles for article (PubMed ID: 29258672)
1. Surrogate end points for overall survival in trials of PD-(L)1 inhibitors for urinary cancers: a systematic review.
Abdel-Rahman O
Immunotherapy; 2018 Feb; 10(2):139-148. PubMed ID: 29260622
[TBL] [Abstract][Full Text] [Related]
2. Immune-mediated thrombocytopenia and hypothyroidism in a lung cancer patient treated with nivolumab.
Jotatsu T; Oda K; Yamaguchi Y; Noguchi S; Kawanami T; Kido T; Satoh M; Yatera K
Immunotherapy; 2018 Feb; 10(2):85-91. PubMed ID: 29260625
[TBL] [Abstract][Full Text] [Related]
3. Comparative effectiveness of immune-checkpoint inhibitors for previously treated advanced non-small cell lung cancer - A systematic review and network meta-analysis of 3024 participants.
Tan PS; Aguiar P; Haaland B; Lopes G
Lung Cancer; 2018 Jan; 115():84-88. PubMed ID: 29290267
[TBL] [Abstract][Full Text] [Related]
4. Severe ophthalmoplegia and myocarditis following the administration of pembrolizumab.
Nasr F; El Rassy E; Maalouf G; Azar C; Haddad F; Helou J; Robert C
Eur J Cancer; 2018 Mar; 91():171-173. PubMed ID: 29287903
[No Abstract] [Full Text] [Related]
5. Pembrolizumab induced acute corneal toxicity after allogeneic stem cell transplantation.
Hsiao CC; Yao M; Liu JH; Chen WL
Clin Exp Ophthalmol; 2018 Aug; 46(6):698-700. PubMed ID: 29280537
[No Abstract] [Full Text] [Related]
6. Polyendocrinopathy Resulting From Pembrolizumab in a Patient With a Malignant Melanoma.
Paepegaey AC; Lheure C; Ratour C; Lethielleux G; Clerc J; Bertherat J; Kramkimel N; Groussin L
J Endocr Soc; 2017 Jun; 1(6):646-649. PubMed ID: 29264517
[TBL] [Abstract][Full Text] [Related]
7. Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab.
Sato K; Akamatsu H; Murakami E; Sasaki S; Kanai K; Hayata A; Tokudome N; Akamatsu K; Koh Y; Ueda H; Nakanishi M; Yamamoto N
Lung Cancer; 2018 Jan; 115():71-74. PubMed ID: 29290265
[TBL] [Abstract][Full Text] [Related]
8. Seeing is believing: anti-PD-1/PD-L1 monoclonal antibodies in action for checkpoint blockade tumor immunotherapy.
Tan S; Zhang CW; Gao GF
Signal Transduct Target Ther; 2016; 1():16029. PubMed ID: 29263905
[TBL] [Abstract][Full Text] [Related]
9. Nivolumab and Ipilimumab in Advanced Melanoma.
Wolchok JD; Rollin L; Larkin J
N Engl J Med; 2017 Dec; 377(25):2503-2504. PubMed ID: 29262279
[No Abstract] [Full Text] [Related]
10. Dynamic Adaptation of Tumor Immune Response With Nivolumab Demonstrated by 18F-FDG PET/CT.
Eshghi N; Lundeen TF; Kuo PH
Clin Nucl Med; 2018 Feb; 43(2):114-116. PubMed ID: 29261621
[TBL] [Abstract][Full Text] [Related]
11. PD-1/PD-L1 in disease.
Kuol N; Stojanovska L; Nurgali K; Apostolopoulos V
Immunotherapy; 2018 Feb; 10(2):149-160. PubMed ID: 29260623
[TBL] [Abstract][Full Text] [Related]
12. Late-Onset Adrenal Insufficiency More Than 1 Year after Stopping Pembrolizumab.
Boudjemaa A; Rousseau-Bussac G; Monnet I
J Thorac Oncol; 2018 Mar; 13(3):e39-e40. PubMed ID: 29472057
[No Abstract] [Full Text] [Related]
13. Myasthenia gravis exacerbation associated with pembrolizumab.
Zhu J; Li Y
Muscle Nerve; 2016 Sep; 54(3):506-7. PubMed ID: 26802533
[No Abstract] [Full Text] [Related]
14. [Pembrolizumab for the treatment of melanoma: updates and perspectives.].
Chiarion Sileni V; Mandalà M; Queirolo P
Recenti Prog Med; 2017 Dec; 108(12):528-531. PubMed ID: 29297903
[TBL] [Abstract][Full Text] [Related]
15. Gastrointestinal: Pembrolizumab-induced gastric ulcer occurring as an immune-related adverse event.
Terasaki K; Ueno A; Mizuno C; Shima T; Okanoue T
J Gastroenterol Hepatol; 2022 Aug; 37(8):1472. PubMed ID: 35141946
[No Abstract] [Full Text] [Related]
16. A Cascade of Pembrolizumab-Induced Autoimmune Toxicities with Mixed Responses to Corticosteroids.
Habib R; Gordon J; Zielinski R
J Thorac Oncol; 2018 Jan; 13(1):e8-e9. PubMed ID: 29258672
[No Abstract] [Full Text] [Related]
17. PD-1 inhibitor-related pneumonitis in lymphoma patients treated with single-agent pembrolizumab therapy.
Nishino M; Ramaiya NH; Hatabu H; Hodi FS; Armand PF
Br J Haematol; 2018 Mar; 180(5):752-755. PubMed ID: 27861725
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
